Review



hela rh cells  (Janssen)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Janssen hela rh cells
    Mutation analysis of amino acid 159 of the CVB3 RdRp
    Hela Rh Cells, supplied by Janssen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hela+rh+cells/pmc05446660-331-6-14?v=Janssen
    Average 90 stars, based on 1 article reviews
    hela rh cells - by Bioz Stars, 2026-07
    90/100 stars

    Images

    1) Product Images from "Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase"

    Article Title: Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase

    Journal: Journal of Virology

    doi: 10.1128/JVI.00487-17

    Mutation analysis of amino acid 159 of the CVB3 RdRp
    Figure Legend Snippet: Mutation analysis of amino acid 159 of the CVB3 RdRp

    Techniques Used: Mutagenesis

    Phenotype of reverse-engineered CVB3 variants. (A) Plaque phenotypes of different CVB3 variants were determined by infecting Vero A cells with a 10-fold serial dilution of each variant, followed by the addition of an agarose overlay. After 3 days, viral plaques were visualized by Giemsa staining. A representative image with spread plaques is shown. (B) Growth curves were generated by infecting Vero A cells with the selected CVB3 variant at an MOI of 3, after which the infectious virus titer in the medium was determined at various time points after infection by plaque assay. Infectious virus titers are the means ± SD of the results of two independent experiments. Significant differences with respect to the WT (*, P < 0.05, or ***, P < 0.001) were analyzed by two-way ANOVA. (C) The sensitivity of the reverse-engineered CVB3 variants to the antiviral effect of T-705 was assessed in HeLa Rh cells by a CPE reduction assay. Cell viability was measured using the MTS/PMS method. Data are expressed as percentages of untreated controls and are mean values ± SD of the results of at least three independent experiments.
    Figure Legend Snippet: Phenotype of reverse-engineered CVB3 variants. (A) Plaque phenotypes of different CVB3 variants were determined by infecting Vero A cells with a 10-fold serial dilution of each variant, followed by the addition of an agarose overlay. After 3 days, viral plaques were visualized by Giemsa staining. A representative image with spread plaques is shown. (B) Growth curves were generated by infecting Vero A cells with the selected CVB3 variant at an MOI of 3, after which the infectious virus titer in the medium was determined at various time points after infection by plaque assay. Infectious virus titers are the means ± SD of the results of two independent experiments. Significant differences with respect to the WT (*, P < 0.05, or ***, P < 0.001) were analyzed by two-way ANOVA. (C) The sensitivity of the reverse-engineered CVB3 variants to the antiviral effect of T-705 was assessed in HeLa Rh cells by a CPE reduction assay. Cell viability was measured using the MTS/PMS method. Data are expressed as percentages of untreated controls and are mean values ± SD of the results of at least three independent experiments.

    Techniques Used: Serial Dilution, Variant Assay, Staining, Generated, Virus, Infection, Plaque Assay



    Similar Products

    hela-rh cells  (KU Leuven)
    90
    KU Leuven hela-rh cells
    Hela Rh Cells, supplied by KU Leuven, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hela+rh+cells/bio_rxiv__2025__01__17__633529-132-0-13?v=KU+Leuven
    Average 90 stars, based on 1 article reviews
    hela-rh cells - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    hela rh cells  (Janssen)
    90
    Janssen hela rh cells
    Mutation analysis of amino acid 159 of the CVB3 RdRp
    Hela Rh Cells, supplied by Janssen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hela+rh+cells/pmc05446660-331-6-14?v=Janssen
    Average 90 stars, based on 1 article reviews
    hela rh cells - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Mutation analysis of amino acid 159 of the CVB3 RdRp

    Journal: Journal of Virology

    Article Title: Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase

    doi: 10.1128/JVI.00487-17

    Figure Lengend Snippet: Mutation analysis of amino acid 159 of the CVB3 RdRp

    Article Snippet: Vero A cells (ATCC CCL-81) and HeLa Rh cells (kindly provided by K. Andries, Janssen Infectious Diseases, Belgium) were maintained in minimal essential medium (MEM Rega-3; Gibco) supplemented with 10% fetal bovine serum (FBS; Gibco), 1% l -glutamine (Gibco), and 1% sodium bicarbonate (Gibco).

    Techniques: Mutagenesis

    Phenotype of reverse-engineered CVB3 variants. (A) Plaque phenotypes of different CVB3 variants were determined by infecting Vero A cells with a 10-fold serial dilution of each variant, followed by the addition of an agarose overlay. After 3 days, viral plaques were visualized by Giemsa staining. A representative image with spread plaques is shown. (B) Growth curves were generated by infecting Vero A cells with the selected CVB3 variant at an MOI of 3, after which the infectious virus titer in the medium was determined at various time points after infection by plaque assay. Infectious virus titers are the means ± SD of the results of two independent experiments. Significant differences with respect to the WT (*, P < 0.05, or ***, P < 0.001) were analyzed by two-way ANOVA. (C) The sensitivity of the reverse-engineered CVB3 variants to the antiviral effect of T-705 was assessed in HeLa Rh cells by a CPE reduction assay. Cell viability was measured using the MTS/PMS method. Data are expressed as percentages of untreated controls and are mean values ± SD of the results of at least three independent experiments.

    Journal: Journal of Virology

    Article Title: Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase

    doi: 10.1128/JVI.00487-17

    Figure Lengend Snippet: Phenotype of reverse-engineered CVB3 variants. (A) Plaque phenotypes of different CVB3 variants were determined by infecting Vero A cells with a 10-fold serial dilution of each variant, followed by the addition of an agarose overlay. After 3 days, viral plaques were visualized by Giemsa staining. A representative image with spread plaques is shown. (B) Growth curves were generated by infecting Vero A cells with the selected CVB3 variant at an MOI of 3, after which the infectious virus titer in the medium was determined at various time points after infection by plaque assay. Infectious virus titers are the means ± SD of the results of two independent experiments. Significant differences with respect to the WT (*, P < 0.05, or ***, P < 0.001) were analyzed by two-way ANOVA. (C) The sensitivity of the reverse-engineered CVB3 variants to the antiviral effect of T-705 was assessed in HeLa Rh cells by a CPE reduction assay. Cell viability was measured using the MTS/PMS method. Data are expressed as percentages of untreated controls and are mean values ± SD of the results of at least three independent experiments.

    Article Snippet: Vero A cells (ATCC CCL-81) and HeLa Rh cells (kindly provided by K. Andries, Janssen Infectious Diseases, Belgium) were maintained in minimal essential medium (MEM Rega-3; Gibco) supplemented with 10% fetal bovine serum (FBS; Gibco), 1% l -glutamine (Gibco), and 1% sodium bicarbonate (Gibco).

    Techniques: Serial Dilution, Variant Assay, Staining, Generated, Virus, Infection, Plaque Assay